Subcutaneous Immunoglobulin Market | Comprehensive Analysis and Future Estimations 2024
According to Transparency Market Research (TMR), the global subcutaneous immunoglobulin market is expected to exhibit a robust 14% CAGR between 2016 and 2024. The market was valued at US$2.7 bn in 2015 and is expected to rise to a valuation of US$8.8 bn by 2024.
By application, primary immunodeficiency diseases accounted for close to 70% of the global subcutaneous immunoglobulin market in 2015 and is likely to dominate the market in the coming years due to the growing prevalence of PIDDs. Geographically, North America is likely to remain the leading contributor to the global subcutaneous immunoglobulin market over the 2016-2024 forecast period due to the steady backing given to the healthcare sector in the region for consistent product improvements, which has resulted in the availability of a diverse array of products in the subcutaneous immunoglobulin market.
Request to download and view full ToC -
Steady Technological Progress Vital for Subcutaneous Immunoglobulin Market
The subcutaneous immunoglobulin market has witnessed impressive growth over the years since the launch of the medicine, and presently there has been a noticeable rise in the adoption of subcutaneous immunoglobulin in developing regions of the world. Therapeutically advanced products that have been recently introduced to the market or are currently in development address unmet needs in two key ways: Attempting to reduce the number of systemic adverse events and formulating concentrated solutions that reduce the infusion time. These new technologies will drive market growth, encouraging further innovation from the next round of startup players.
New products are being developed in the subcutaneous immunoglobulin market that aim to improve and facilitate subcutaneous administration of immunoglobulins. For instance, hyaluronidase-facilitated administration increases the bioavailability of SCIG and allows administration of large volumes at a single site. Hyquia, developed by Shire Plc., is one such formulation, supplied in a dual vial unit containing one vial of immunoglobulin infusion 10% and one vial of recombinant human hyaluronidase. The companies are producing more concentrated formulations that will reduce the volume required for administration. For instance, Cuvitru, developed by Shire Plc., is a subcutaneous immunoglobulin 20% solution, with the ability to infuse up to 60 mL (12 grams) per site per hour resulting in shorter infusion durations and fewer infusion sites compared to other conventional subcutaneous treatments. As these developments convert into clinical practice, more patients and physicians may choose the subcutaneous route for administration of immunoglobulin in future.
Request to view Sample Report -
The growing government support to measures combating the spread of deadly diseases such as AIDS is likely to help the subcutaneous immunoglobulin market’s progress in the coming years. While primary immunodeficiency diseases are the primary target for subcutaneous immunoglobulin market players, AIDS treatment could contribute significantly to the market in the coming years. The rising demand for home care in various medical channels is also likely to help the subcutaneous immunoglobulin market, as it will allow for widespread adoption of the infrastructure needed to enable in-home administration of subcutaneous immunoglobulin on a large scale.
Subcutaneous Immunoglobulin Market Report is available @ US$ 5795
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Subcutaneous Immunoglobulin Market | Comprehensive Analysis and Future Estimations 2024 here
News-ID: 735298 • Views: 136
More Releases from Transparecny Market Research
Pharmaceutical Water Market Trending Attributes Creating Positive Impact On The …
Pharmaceutical Water Market – Scope of the Report TMR’s report on the global pharmaceutical water market studies the past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2020 to 2030. The report provides the revenue of the global pharmaceutical water market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast
Advanced Wound Care Management Market - Global Industry Analysis, Size, Share, G …
Advanced Wound Care Management Market - Overview The market for wound care is expanding significantly, due to increase in advancements in treating complex wounds. The advanced wound care market is anticipated to expand during the forecast period, as the products have been a promising solution for rapid recovery and wound healing. These products offer superior solution than traditional products by offering desired outcome and effectiveness in healing wounds. Increasing incidences of
Operating Room Equipment Market projected to expand at a CAGR of 6.4% from 2018 …
Transparency Market Research (TMR) has published a new report titled ‘Operating room equipment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.’ According to the report, the global operating room equipment market was valued at US$ 29,912.3 Mn in 2017. It is projected to expand at a CAGR of 6.4% from 2018 to 2026. Aging population and longer life-expectancy, increased awareness, and acceptance of advanced devices are
Hip Replacement Implants Market Size, Status, Scope and Growth Prospects
The global hip replacement implants market was valued at approximately US$ 7.0 Bn in 2017. It is projected to register a cumulative annual growth rate (CAGR) of over 3.5% from 2018 to 2026, according to a new report published by Transparency Market Research (TMR) titled ‘Hip Replacement Implants Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.’ Expansion of the health care industry, government initiatives, increase in
More Releases for Subcutaneous
Subcutaneous Injector Sales Market Report 2017
Subcutaneous Injector market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Browse the full report with a table of contents : https://www.reportsandmarkets.com/reports/global-subcutaneous-injector-sales-market-report-2017-1701051 Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Subcutaneous Injector for
US$ 9 Bn Opportunity in Global Subcutaneous Immunoglobulin Market
The global subcutaneous immunoglobulin market is projected to grow at double-digit CAGR through 2024. Demand for subcutaneous immunoglobulin products is influenced by increasing focus on treating primary immunodeficiency diseases. The healthcare infrastructure in many emerging countries has gained center stage owing to concerted efforts on part of governments. On account of these factors, the global subcutaneous immunoglobulin market is expected to reach nearly US$ 9 bn by 2024. These insights
Unmet Need Remains for Subcutaneous Sustained Release Injectables
(Amherst, NH) - As patients live longer and the prevalence and incidence of chronic ailments increase across the general population, drug developers and their delivery device partners are adapting to address what will become a significant market opportunity. Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration and reduced dosing frequency. With the shift away from caregiver interaction, drug safety and compliance/adherence
Global Subcutaneous Immunoglobulin Market | MarketResearchReports.biz
Latest industry research report on: Global Subcutaneous Immunoglobulin Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Global Subcutaneous Immunoglobulin Market: Overview Primary humoral immunodeficiency or primary immune deficiency diseases (PIDD) is a group of disorders in which the immune system of an individual does not function properly. In PIDD patients, the number of antibodies produced in the body is not sufficient, or the ones produced are
Subcutaneous Immunoglobulin Market Research Report : Forecast up to 2024
Key companies in The Global Subcutaneous Immunoglobulin Market include Grifols S.A., CSL Behring LLC, Shire Plc., Biotest AG, Kedrion S.p.A., Octapharma AG, Baxalta Incorporated, and Talecris Biotherapeutics, Inc. The global subcutaneous immunoglobulin market is likely to present an opportunity-filled landscape for new players in the coming years, while steady expansion efforts are likely to help existing market players consolidate their position in the subcutaneous immunoglobulin market. According to Transparency Market Research
Subcutaneous Immunoglobulin Market Demand and Growth Upto 2024
Immunoglobulin, commonly known as an antibody, is a Y-shaped protein manufactured primarily by plasma cells. Immunoglobulin is utilized by the immune system to counterbalance pathogens. Subcutaneous injections are administered as vaccines and medications including insulin and immunoglobulin. The process of administering immunoglobulin is known as immunoglobulin therapy. When immunoglobulin therapy is applied below the dermis and epidermis, or cutis, it is known as subcutaneous immunoglobulin. Subcutaneous therapy is useful as